×
About 2,993 results

ALLMedicine™ Autoimmune Hepatitis Center

Research & Reviews  1,085 results

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF AUTOIMMUNE HEPATITIS.
https://doi.org/10.1016/j.clinre.2021.101772
Clinics and Research in Hepatology and Gastroenterology; Lemoinne S, Heurgue A et. al.

Aug 1st, 2021 - Autoimmune hepatitis (AIH) is a liver disease characterised by necrotico-inflammatory lesions of hepatocytes, the presence of specific autoantibodies and response to corticosteroid treatment. AIH must be considered in any patient with acute or chr...

Autoimmune hepatitis triggered by SARS-CoV-2 vaccination.
https://doi.org/10.1016/j.jaut.2021.102710
Journal of Autoimmunity; Vuille-Lessard É, Montani M et. al.

Aug 1st, 2021 - The development of autoimmune diseases has been reported after SARS-CoV-2 infection. Vaccination against SARS-CoV-2 could also trigger auto-immunity, as it has been described with other vaccines. An aberrant immune response induced by molecular mi...

Primary adrenal insufficiency due to bilateral adrenal infarction in COVID-19: a case r...
https://doi.org/10.1210/clinem/dgab557
The Journal of Clinical Endocrinology and Metabolism; Machado IFR, Menezes IQ et. al.

Jul 30th, 2021 - Coronavirus disease 2019 (COVID-19) is a proinflammatory and prothrombotic condition, but its impact on adrenal function has not been adequately evaluated. A 46-year-old woman presented with abdominal pain, hypotension, skin hyperpigmentation afte...

Behaviors, symptoms, and outcomes of North American patients with autoimmune hepatitis ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318716
Journal of Investigative Medicine : the Official Publicat... Vuppalanchi V, Gelow K et. al.

Jul 29th, 2021 - The management of patients with autoimmune hepatitis (AIH) in the era of SARS-CoV-2 is challenging given minimal published clinical data. We used a large cohort of patients with AIH across the USA to investigate the differences in known risk facto...

Postinfantile giant cell hepatitis in the setting of autoimmune hepatitis: exclusively ...
https://doi.org/10.1136/bcr-2021-243660
BMJ Case Reports; Teles C, Santos R et. al.

Jul 23rd, 2021 - Autoimmune hepatitis (AIH) is a rare chronic liver disease with a non-specific clinical presentation. Its physiopathology is not fully understood and, if untreated, can progress to cirrhosis and even fulminant liver failure. Here, we describe a ca...

see more →

Guidelines  4 results

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF AUTOIMMUNE HEPATITIS.
https://doi.org/10.1016/j.clinre.2021.101772
Clinics and Research in Hepatology and Gastroenterology; Lemoinne S, Heurgue A et. al.

Aug 1st, 2021 - Autoimmune hepatitis (AIH) is a liver disease characterised by necrotico-inflammatory lesions of hepatocytes, the presence of specific autoantibodies and response to corticosteroid treatment. AIH must be considered in any patient with acute or chr...

Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice ...
https://doi.org/10.1002/hep.31065
Hepatology (Baltimore, Md.); Mack CL, Adams D et. al.

Dec 22nd, 2019 - Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases.|2019|Mack CL,Adams D,Assis DN,Kerkar N,Manns MP,|diagnosis,drug therapy,

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.

Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...

Diagnosis and management of autoimmune hepatitis.
https://doi.org/10.1002/hep.23584
Hepatology (Baltimore, Md.); Manns MP, Czaja AJ et. al.

Jun 1st, 2010 - Diagnosis and management of autoimmune hepatitis.|2010|Manns MP,Czaja AJ,Gorham JD,Krawitt EL,Mieli-Vergani G,|blood,diagnosis,drug therapy,immunology,pathology,

see more →

Drugs  8 results see all →

Clinicaltrials.gov  20 results

Budesonide for Liver Transplant Immune Suppression
https://clinicaltrials.gov/ct2/show/NCT03304626

Mar 24th, 2020 - Enrollment of Subjects: All consecutive patients undergoing liver transplant (LT) at the University Of Cincinnati Transplant Center will be screened for enrollment upon admission for transplant surgery. Subjects will be approached after permission...

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade
https://clinicaltrials.gov/ct2/show/NCT03217422

Mar 12th, 2020 - This is a randomized, placebo-controlled, double-blind dose range study in autoimmune hepatitis. The study population consists of female and male adult autoimmune hepatitis patients with incomplete response or intolerant to standard treatment of c...

Biomarkers to Predict the Success of Immunosuppression Withdrawal in Autoimmune Hepatitis
https://clinicaltrials.gov/ct2/show/NCT03711669

Feb 12th, 2020 - Study design: This is a prospective not controlled, not randomized, unicentric study to establish predictive biomarkers for a safe and effective treatment withdrawal in patients with type 1 AIH. Length of the study: Screening is expected to take a...

Assessing Kids for Liver Inflammation and Fibrosis Using Non-invasive MRI
https://clinicaltrials.gov/ct2/show/NCT03198104

Sep 17th, 2018 - The most serious pandemic facing Europe is fatty liver disease and non-alcoholic steatohepatitis (NASH). The main causal factor is obesity: according to recent statistics 11.8m-16.3m European children are overweight, of which 2.9m - 4.4m are obese...

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
https://clinicaltrials.gov/ct2/show/NCT01988506

Aug 20th, 2018 - Protocol: TRANSREG is a multicentric, uncontrolled, open-label study, comparing biological and clinical responses to the administration of low doses IL2 across 14 selected pathologies: rheumatoid arthritis, ankylosing spondylitis, systemic lupus e...

see more →

News  75 results

Worse Survival With Recurrent Autoimmune Hepatitis After Transplant
https://www.medscape.com/viewarticle/954067

Jul 1st, 2021 - Autoimmune hepatitis that recurs following a liver transplant can impair both graft survival and overall survival, results of a large international study showed. Among 736 patients with autoimmune hepatitis who underwent liver transplant and were ...

Incidence of Autoimmune Hepatitis May Be Rising
https://www.medscape.com/viewarticle/945131

Feb 2nd, 2021 - The incidence of autoimmune hepatitis (AIH) may be rising, according to a prospective population-based study conducted in New Zealand. From 2008 to 2016, the rising incidence of AIH led to a 40% increase in point prevalence, reported lead author M...

Treating Liver Disease During COVID-19: New Recommendations
https://www.medscape.com/viewarticle/930411

May 14th, 2020 - Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The COVID-19 pandemic presents myriad challenges to hepatologists, gastroenterologists, transplant programs, primary care providers, and, of course, their patien...

AASLD: Liver transplants should proceed despite COVID-19
https://www.mdedge.com/gihepnews/article/220026/coronavirus-updates/aasld-liver-transplants-should-proceed-despite-covid-19?channel=63993
M. Alexander Otto, MDedge News

Apr 1st, 2020 - In liver transplant recipients or patients with autoimmune hepatitis on immunosuppressive therapy, acute cellular rejection or disease flare should not be presumed in the face of active coronavirus disease 2019 (COVID-19), according to the America.

CymaBay Therapeutics scraps two studies of liver drug; shares plunge
https://www.reuters.com/article/us-cymabay-nash/cymabay-therapeutics-scraps-two-studies-of-liver-drug-shares-plunge-idUSKBN1XZ1MC

Nov 25th, 2019 - (Reuters) - CymaBay Therapeutics Inc said on Monday it was scrapping two mid-stage trials of its liver disease drug, after biopsies found a type of liver damage in some patients, sending its shares down over 75%. The drug developer said it had obs...

see more →

Patient Education  5 results see all →